S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.19
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.52
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
18.45
+1.77
+10.61%
LXRX · Lexicon Pharmaceuticals, Inc.
NASDAQ NMS - GLOBAL MARKET - Real Time Price • USD
Lexicon Pharmaceuticals Inc (LXRX)
NASDAQ NMS - GLOBAL MARKET
Pharmaceuticals
$1.55
-0.02
(-1.59%)
● At close: October 21 at 4:00:00 PM EDT
DAY'S RANGE
$1.55
$1.55
$1.61
52-WEEK RANGE
$1.55
$1.10
$2.68
What's happening
- LXRX is down 1.59% today, trading at $1.55. — Live quote
- Volume today (106,894) is well below its 3-month average of 3,249,420. (Finnhub fundamentals)
- Reports earnings on 2026-11-11, 20 days away. (Finnhub earnings calendar)
- Last quarter's EPS missed estimates: $-0.07 actual vs. $-0.05 estimated (-36.7%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 3
Buy 6
Hold 3
Sell 0
Strong sell 0
Aggregate ratings for 2026-10-01 (12 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
LXRX
+37.39%
vs S&P 500
+24.61%
1-YEAR RETURN
LXRX
+3.95%
vs S&P 500
-10.61%
6-MONTH RETURN
LXRX
-14.13%
3-MONTH RETURN
LXRX
-33.61%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$-0.07
Est. $-0.05
MISS -36.7%
2026-04-26 (Q1 2026)
$0.00
Est. $-0.04
BEAT +100.0%
2026-01-26 (Q4 2025)
$-0.04
Est. $-0.07
BEAT +43.2%
2025-10-26 (Q3 2025)
$-0.04
Est. $-0.07
BEAT +40.6%
Valuation Measures & Ratios
Enterprise Value4$715.8M
Forward P/E5—
PEG Ratio6—
Price / Sales (TTM1)17.01
Price / Book76.11
EV4 / Revenue17.26
EV4 / EBITDA16.80
Profit Margin-147.38%
Operating Margin-141.92%
Return on Equity (ROE8)-40.40%
Return on Assets (ROA9)-26.87%
Avg Volume (3M)3,249,420
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $1.08B | — | $431.0M | $308.9M | $167.3M |
| P/E | -25.63 | — | -4.33 | -2.20 | -0.87 |
| Price/Sales | 16.73 | — | 9.36 | 9.21 | 28.89 |
| Price/Book | 6.22 | — | 3.59 | 2.39 | 1.36 |
| EV/Revenue | 16.89 | — | 9.51 | 10.25 | 35.43 |
| EV/EBITDA | -30.90 | — | -4.50 | — | — |
| ROE | -24.26% | — | -82.91% | -108.38% | -156.00% |
| ROA | -16.93% | — | -48.38% | -62.19% | -64.48% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short25,828,112
Change from Prior Settlement-10.30%
% of Float—
Days to Cover (Short Ratio)6.16
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Trailing 52-week price return is +3.9%. Finnhub market metrics ↗
- Latest SEC filing is Form 10-Q, filed 2026-08-06; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Revenue growth is -97.6% on the provider's reported measure. Finnhub fundamentals ↗
- Net profit margin is -147.4%. Finnhub fundamentals ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on LXRX
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $692.0K | $21.1M | $14.2M | $28.9M | $1.3M | $1.8M | $1.6M | $1.1M |
| Operating income | -$26.5M | -$996.0K | -$12.2M | $3.7M | -$25.7M | -$63.7M | -$55.4M | -$45.3M |
| Net income | -$31.8M | -$1.0M | -$12.8M | $3.3M | -$25.3M | -$64.8M | -$53.4M | -$48.4M |
| EPS (diluted) | $-0.07 | $0.00 | $-0.04 | $0.01 | $-0.07 | $-0.18 | $-0.17 | $-0.20 |
| EPS (basic) | $-0.07 | $0.00 | $-0.04 | $0.01 | $-0.07 | $-0.18 | $-0.17 | $-0.20 |
| Operating margin | -$3.8K | -$5 | -$86 | $13 | -$2.0K | -$3.6K | -$3.4K | -$4.0K |
| Net margin | -$4.6K | -$5 | -$90 | $11 | -$2.0K | -$3.7K | -$3.2K | -$4.3K |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $250.1M | $268.8M | $185.0M | $205.9M | $225.6M | $297.7M | $298.4M | $321.1M |
| Total liabilities | $75.5M | $66.0M | $77.4M | $85.8M | $96.1M | $174.6M | $152.5M | $142.6M |
| Stockholders' equity | $174.5M | $202.9M | $107.5M | $120.2M | $129.4M | $123.0M | $145.9M | $178.5M |
| Total current assets | $196.6M | $186.0M | $101.9M | $122.5M | $145.1M | $245.8M | $246.2M | $268.6M |
| Total current liabilities | $14.7M | $9.9M | $20.9M | $21.7M | $34.8M | $110.7M | $45.2M | $36.0M |
| Cash & equivalents | $40.9M | $38.1M | $34.3M | $49.7M | $21.4M | $62.9M | $66.7M | $34.6M |
| Marketable securities (current) | $149.7M | $132.6M | $61.9M | $66.3M | $117.6M | $132.0M | $171.3M | $223.8M |
| Accounts receivable | $1.6M | $11.8M | $2.4M | $2.3M | $2.2M | $47.4M | $3.5M | $2.9M |
| Inventory | $1.2M | $276.0K | $281.0K | $158.0K | $168.0K | $201.0K | $231.0K | $636.0K |
| Other current assets | $3.1M | $3.3M | $3.0M | $4.1M | $3.7M | $3.3M | $4.5M | $6.7M |
| Property, plant & equipment | $1.7M | $1.8M | $1.9M | $2.0M | $2.1M | $2.3M | $2.5M | $2.1M |
| Goodwill | $44.5M | $44.5M | $44.5M | $44.5M | $44.5M | $44.5M | $44.5M | $44.5M |
| Intangible assets | — | — | — | — | — | — | — | — |
| Other non-current assets | $368.0K | $368.0K | $368.0K | $368.0K | $368.0K | $368.0K | $368.0K | $828.0K |
| Accounts payable | $2.3M | $3.0M | $3.1M | $3.8M | $5.9M | $10.7M | $14.8M | $14.2M |
| Accrued liabilities | $12.4M | $6.9M | $13.2M | $13.6M | $11.5M | $12.9M | $30.4M | $21.8M |
| Deferred revenue (current) | — | — | — | $4.3M | $17.5M | — | $0 | — |
| Short-term debt | $0 | $0 | $4.6M | — | — | $42.1M | $0 | — |
| Long-term debt | $51.4M | $49.7M | $49.4M | $56.5M | $56.1M | $58.6M | $100.3M | $99.9M |
| Other non-current liabilities | $9.4M | $6.4M | $7.2M | $7.5M | $5.2M | $5.3M | $6.9M | $6.7M |
| Common stock & paid-in capital | $447.0K | $426.0K | $366.0K | $366.0K | $366.0K | $366.0K | $363.0K | $363.0K |
| Retained earnings | -$2.05B | -$2.02B | -$2.02B | -$2.00B | -$1.99B | -$1.99B | -$1.97B | -$1.93B |
| Accumulated other comprehensive income (loss) | -$204.0K | -$130.0K | $30.0K | $29.0K | -$14.0K | $25.0K | $119.0K | $349.0K |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$9.2M | -$14.7M | -$17.2M | -$23.8M | $17.0M | -$43.8M | -$21.5M | -$53.6M |
| Investing cash flow | -$16.5M | -$70.3M | $4.8M | $52.1M | $15.5M | $40.6M | $53.7M | $53.5M |
| Financing cash flow | -$512.0K | $88.8M | -$2.9M | $0 | -$45.0M | -$572.0K | -$104.0K | -$916.0K |
| Free cash flow | — | — | -$17.2M | -$23.8M | $17.0M | — | -$22.0M | -$53.9M |
| Capital expenditures | — | — | $0 | $0 | $0 | — | $474.0K | $307.0K |
| Depreciation & amortization | $102.0K | $110.0K | $118.0K | $151.0K | $176.0K | $176.0K | $125.0K | $126.0K |
| Share-based compensation | $3.3M | $3.1M | $2.8M | $3.4M | $3.2M | $3.0M | $1.5M | $2.8M |
| Deferred income taxes | — | — | — | — | — | — | — | — |
| Change in accounts receivable | -$10.1M | $9.4M | $50.0K | $151.0K | -$264.0K | -$1.0M | $578.0K | $275.0K |
| Change in inventory | $920.0K | -$5.0K | $123.0K | -$10.0K | -$33.0K | -$30.0K | -$405.0K | $51.0K |
| Purchases of investments | $57.3M | $106.0M | $22.2M | $26.7M | $26.0M | $65.0M | $25.8M | $42.6M |
| Share repurchases | — | — | — | — | — | — | $0 | $0 |
| Debt issued | — | — | $0 | — | — | — | $0 | $0 |
| Debt repaid | — | — | — | — | — | — | — | — |
| Tax withholding on stock comp | $0 | $2.8M | $0 | $0 | $0 | $572.0K | $0 | $0 |
| Other financing activities | -$2.3M | — | $0 | $0 | $0 | $0 | -$1.0K | -$906.0K |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | $49.8M | $31.1M | $1.2M | $139.0K | $298.0K |
| Operating income | -$48.9M | -$197.1M | -$171.8M | -$100.8M | -$87.1M |
| Net income | -$50.3M | -$200.4M | -$177.1M | -$101.9M | -$87.8M |
| EPS (diluted) | $-0.14 | $-0.63 | $-0.80 | $-0.62 | $-0.60 |
| EPS (basic) | $-0.14 | $-0.63 | $-0.80 | $-0.62 | $-0.60 |
| Operating margin | -$98 | -$634 | -$14.3K | -$72.5K | -$29.2K |
| Net margin | -$101 | -$645 | -$14.7K | -$73.3K | -$29.4K |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $185.0M | $298.4M | $229.4M | $194.3M | $136.9M |
| Total liabilities | $77.4M | $152.5M | $136.3M | $77.2M | $23.3M |
| Stockholders' equity | $107.5M | $145.9M | $93.1M | $117.1M | $113.6M |
| Total current assets | $101.9M | $246.2M | $176.5M | $140.9M | $88.9M |
| Total current liabilities | $20.9M | $45.2M | $31.5M | $23.2M | $22.1M |
| Cash & equivalents | $34.3M | $66.7M | $22.5M | $46.3M | $64.1M |
| Marketable securities (current) | $61.9M | $171.3M | $147.6M | $92.0M | $22.7M |
| Accounts receivable | $2.4M | $3.5M | $1.0M | $28.0K | $14.0K |
| Inventory | $281.0K | $231.0K | $381.0K | $0 | — |
| Other current assets | $3.0M | $4.5M | $5.1M | $2.5M | $2.2M |
| Property, plant & equipment | $1.9M | $2.5M | $2.0M | $2.1M | $1.2M |
| Goodwill | $44.5M | $44.5M | $44.5M | $44.5M | $44.5M |
| Other non-current assets | $368.0K | $368.0K | $828.0K | $412.0K | $2.3M |
| Accounts payable | $3.1M | $14.8M | $14.4M | $10.4M | $9.2M |
| Accrued liabilities | $13.2M | $30.4M | $17.2M | $12.8M | $13.0M |
| Short-term debt | $4.6M | $0 | — | — | $0 |
| Long-term debt | $49.4M | $100.3M | $99.5M | $48.6M | $0 |
| Other non-current liabilities | $7.2M | $6.9M | $5.3M | $5.4M | $1.2M |
| Common stock & paid-in capital | $366.0K | $363.0K | $245.0K | $189.0K | $150.0K |
| Retained earnings | -$2.02B | -$1.97B | -$1.77B | -$1.59B | -$1.49B |
| Accumulated other comprehensive income (loss) | $30.0K | $119.0K | $31.0K | -$428.0K | -$10.0K |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$67.9M | -$178.8M | -$161.9M | -$88.9M | -$87.0M |
| Investing cash flow | $113.0M | -$15.4M | -$49.9M | -$71.1M | $2.1M |
| Financing cash flow | -$48.5M | $238.3M | $188.0M | $142.2M | $22.7M |
| Free cash flow | -$67.9M | -$179.8M | -$162.4M | -$90.2M | -$88.2M |
| Capital expenditures | $0 | $1.0M | $470.0K | $1.3M | $1.2M |
| Depreciation & amortization | $621.0K | $534.0K | $554.0K | $427.0K | $292.0K |
| Share-based compensation | $12.5M | $13.5M | $14.3M | $11.5M | $10.6M |
| Deferred income taxes | — | — | — | $0 | $0 |
| Change in accounts receivable | -$1.1M | $2.5M | $982.0K | $14.0K | -$381.0K |
| Change in inventory | $50.0K | -$150.0K | $381.0K | $0 | $0 |
| Purchases of investments | $139.8M | $328.7M | $223.3M | $133.9M | $34.3M |
| Share repurchases | — | $1.7M | $824.0K | $864.0K | $2.7M |
| Debt issued | $0 | $0 | $50.0M | $48.9M | — |
| Debt repaid | — | — | — | -$48.9M | $11.7M |
| Tax withholding on stock comp | $572.0K | $1.7M | $824.0K | — | — |
| Other financing activities | $0 | -$1.3M | $0 | $0 | — |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding LXRX as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Institutional ownership is not available for this symbol right now.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2026-02-23 to 2026-06-03
Recent transactions
- Most recent: Swain Judith L (Director) — Option exercise of 89,312 shares on 2026-06-03.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)0 sh(0 txns)
Sales (open market)0 sh(0 txns)
Net Shares+0
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Swain Judith L | Director | Option exercise | 2026-06-03 | 89,312 |
| Sullivan Diane E. | Director | Option exercise | 2026-06-03 | 89,312 |
| SOBECKI CHRISTOPHER J | Director | Option exercise | 2026-06-03 | 89,312 |
| Cheung Ivan | Director | Option exercise | 2026-06-03 | 89,312 |
| BARKER SAM L | Director | Option exercise | 2026-06-03 | 89,312 |
| Amouyal Philippe | Director | Option exercise | 2026-06-03 | 89,312 |
| DEBBANE RAYMOND | Director | Option exercise | 2026-06-03 | 89,312 |
| Artal Participations S.a r.l. | Reporting person | Option exercise | 2026-04-30 | 20,421,735 |
| McDermott Wendy | SVP, Human Resources | Option exercise | 2026-02-28 | 27,697 |
| Martens Rachel Yap | SVP, Partnerships & Corp Strat | Option exercise | 2026-02-28 | 67,090 |
| Granowitz Craig B | SVP, Chief Medical Officer | Option exercise | 2026-02-28 | 35,790 |
| Gopinathan Suma | SVP, Discovery | Option exercise | 2026-02-28 | 14,000 |
| DeFrancesco Lisa | SVP, IR and Corp Comm | Option exercise | 2026-02-28 | 24,674 |
| Crum Brian T | SVP, General Counsel & Secr. | Option exercise | 2026-02-28 | 33,457 |
| Coiante Scott M | SVP, Chief Financial Officer | Option exercise | 2026-02-28 | 160,237 |
| Exton Michael | Chief Executive Officer | Option exercise | 2026-02-28 | 503,263 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-06-03 | Swain Judith L | Director | Option exercise | 89,312 | $0.00 |
| 2026-06-03 | Sullivan Diane E. | Director | Option exercise | 89,312 | $0.00 |
| 2026-06-03 | SOBECKI CHRISTOPHER J | Director | Option exercise | 89,312 | $0.00 |
| 2026-06-03 | Cheung Ivan | Director | Option exercise | 89,312 | $0.00 |
| 2026-06-03 | BARKER SAM L | Director | Option exercise | 89,312 | $0.00 |
| 2026-06-03 | Amouyal Philippe | Director | Option exercise | 89,312 | $0.00 |
| 2026-06-03 | DEBBANE RAYMOND | Director | Option exercise | 89,312 | $0.00 |
| 2026-04-30 | Artal Participations S.a r.l. | Reporting person | Option exercise | 20,421,735 | $0.00 |
| 2026-02-28 | McDermott Wendy | SVP, Human Resources | Option exercise | 27,697 | — |
| 2026-02-28 | McDermott Wendy | SVP, Human Resources | Option exercise | 52,316 | — |
| 2026-02-28 | McDermott Wendy | SVP, Human Resources | Option exercise | 144,393 | — |
| 2026-02-28 | McDermott Wendy | SVP, Human Resources | Tax withholding | 68,107 | $1.47 |
| 2026-02-28 | Martens Rachel Yap | SVP, Partnerships & Corp Strat | Option exercise | 67,090 | — |
| 2026-02-28 | Martens Rachel Yap | SVP, Partnerships & Corp Strat | Tax withholding | 35,826 | $1.47 |
| 2026-02-28 | Granowitz Craig B | SVP, Chief Medical Officer | Option exercise | 35,790 | — |
| 2026-02-28 | Granowitz Craig B | SVP, Chief Medical Officer | Option exercise | 74,226 | — |
| 2026-02-28 | Granowitz Craig B | SVP, Chief Medical Officer | Option exercise | 202,260 | — |
| 2026-02-28 | Granowitz Craig B | SVP, Chief Medical Officer | Tax withholding | 109,098 | $1.47 |
| 2026-02-28 | Gopinathan Suma | SVP, Discovery | Option exercise | 14,000 | — |
| 2026-02-28 | Gopinathan Suma | SVP, Discovery | Option exercise | 20,310 | — |
| 2026-02-28 | Gopinathan Suma | SVP, Discovery | Option exercise | 65,640 | — |
| 2026-02-28 | Gopinathan Suma | SVP, Discovery | Tax withholding | 24,338 | $1.47 |
| 2026-02-28 | DeFrancesco Lisa | SVP, IR and Corp Comm | Option exercise | 24,674 | — |
| 2026-02-28 | DeFrancesco Lisa | SVP, IR and Corp Comm | Option exercise | 128,190 | — |
| 2026-02-28 | DeFrancesco Lisa | SVP, IR and Corp Comm | Tax withholding | 74,572 | $1.47 |
| 2026-02-28 | Crum Brian T | SVP, General Counsel & Secr. | Option exercise | 33,457 | — |
| 2026-02-28 | Crum Brian T | SVP, General Counsel & Secr. | Option exercise | 69,386 | — |
| 2026-02-28 | Crum Brian T | SVP, General Counsel & Secr. | Option exercise | 170,163 | — |
| 2026-02-28 | Crum Brian T | SVP, General Counsel & Secr. | Tax withholding | 105,019 | $1.47 |
| 2026-02-28 | Coiante Scott M | SVP, Chief Financial Officer | Option exercise | 160,237 | — |
| 2026-02-28 | Coiante Scott M | SVP, Chief Financial Officer | Tax withholding | 54,881 | $1.47 |
| 2026-02-28 | Exton Michael | Chief Executive Officer | Option exercise | 503,263 | — |
| 2026-02-28 | Exton Michael | Chief Executive Officer | Tax withholding | 204,831 | $1.47 |
| 2026-02-25 | DEBBANE RAYMOND | Director | Open market purchase | 2,000 | $1.49 |
| 2026-02-23 | DEBBANE RAYMOND | Director | Open market purchase | 100,000 | $1.47 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 08:40 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-08-06 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-08-06 | 8-K | 2026-08-06 | View on SEC.gov → |
| 2026-06-04 | 4 | 2026-06-03 | View on SEC.gov → |
| 2026-06-04 | 4 | 2026-06-03 | View on SEC.gov → |
| 2026-06-04 | 4 | 2026-06-03 | View on SEC.gov → |
| 2026-06-04 | 4 | 2026-06-03 | View on SEC.gov → |
| 2026-06-04 | 4 | 2026-06-03 | View on SEC.gov → |
| 2026-06-04 | 4 | 2026-06-03 | View on SEC.gov → |
| 2026-06-04 | 4 | 2026-06-03 | View on SEC.gov → |
| 2026-05-08 | 4 | 2026-04-30 | View on SEC.gov → |
| 2026-05-07 | 10-Q | 2026-03-31 | View on SEC.gov → |
| 2026-05-07 | 8-K | 2026-05-07 | View on SEC.gov → |
Recent news
Headlines about LXRX (Lexicon Pharmaceuticals, Inc.). Links open the publisher — we don’t host full articles.
-
Lexicon Pharmaceuticals Announces Publication of New Research Highlighting Sotagliflozin’s Biological Effects in Cardiovascular Disease
Yahoo · 2026-10-21 -
Lexicon Highlights Preclinical Studies Showing Biological Effects Of Sotagliflozin In Hypertrophic Cardiomyopathy And Thrombotic Disease Pathways
Benzinga · 2026-10-21 -
AIRG,EML,HGBL,ATLO,CULP,SLRC,VANI,HASI,FBK,LXRX,ASYS,SFST,BRID,ASLE,RMCF,NVCT | Stock Prices | Quote Comparison
Yahoo! Finance Canada · 2026-10-21 -
AIRG,EML,HGBL,ATLO,CULP,SLRC,FBK,VANI,HASI,LXRX,ASYS,SFST,BRID,ASLE,RMCF,NVCT | Stock Prices | Quote Comparison - Yahoo Finance
Yahoo! Finance Canada · 2026-10-20 -
LXRX Nov 2026 1.500 call (LXRX261120C00001500) Stock Price, News, Quote & History
Yahoo! Finance Canada · 2026-10-19 -
LXRX270416C00001000 interactive stock chart | LXRX Apr 2027 1.000 call stock
Yahoo Finance UK · 2026-10-19 -
AIRG,DOMH,HGBL,SLND,SLRC,VANI,FBK,HASI,LXRX,SFST,ASYS,ASLE,RMCF,NVCT,CMTL | Stock Prices | Quote Comparison
Yahoo! Finance Canada · 2026-10-18 -
LXRX Q2 2026 Earnings: Wider-Than-Expected Loss Sends Shares Down 7.88% - Revenue Recognition Risk
https://www.siam.in/ · 2026-10-16
No headlines in this category right now — try “All”.